Wegovy Maker Strikes $1B Deal for Next-Gen Obesity TreatmentNovo Nordisk acquires global rights to Lexicon's obesity drug LX9851, aiming to enhance its position in the obesity treatment market.
Novo Nordisk Just Bought the Next Big Thing in Weight LossNovo Nordisk secures global rights to Triple-G weight loss therapy through a licensing deal, targeting three hormones for better results.
CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats PlaceboNovo Nordisk's CagriSema obesity treatment underperformed in trials, showing lower weight loss than anticipated compared to Wegovy.
FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage BleedingNovo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese AdultsNovo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity TreatmentAnalysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Must-Reads
1
Trump Claims Epstein 'Stole' Young Women from Mar-a-Lago Spa
LATEST
2
Say Hello to Your New Beauty Buddy: AI-Powered Kiosks Hit GS25 Stores!
LATEST
3
New Task Force Takes Aim at Stock Manipulators: A Game Changer for Investors!
LATEST
4
COP30 Chaos: Will Brazil's Soaring Hotel Prices Keep Poor Nations Out of Climate Talks?
LATEST
5
Is Tesla Behind LG Energy's Massive Battery Supply Contract?
Wegovy Maker Strikes $1B Deal for Next-Gen Obesity Treatment Novo Nordisk acquires global rights to Lexicon's obesity drug LX9851, aiming to enhance its position in the obesity treatment market.
Novo Nordisk Just Bought the Next Big Thing in Weight Loss Novo Nordisk secures global rights to Triple-G weight loss therapy through a licensing deal, targeting three hormones for better results.
CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats Placebo Novo Nordisk's CagriSema obesity treatment underperformed in trials, showing lower weight loss than anticipated compared to Wegovy.
FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage Bleeding Novo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese Adults Novo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity Treatment Analysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Hot Topics